About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 66 record(s)
Req # A-2019-000354
All correspondence between FSD Pharma Inc. and Heath Canada from August 1, 2018 to June 4, 2019 regarding an application(s) for or issuing of any license(s) or permit(s).Organization: Health Canada
April 2020
Req # A-2019-000440
Any correspondence between any representative of Health Canada and any representative of Purdue Pharmaceutical or Purdue Pharma in regards to adverse reactions of OxyContin, including the adverse reaction of death.Organization: Health Canada
April 2020
Req # A-2019-000441
Any correspondence between Health Canada and any representative of Purdue Pharmaceutical in regards to any deceptive or manipulative marketing practices by the company in the sales of any of its products, in particular, of OyxContin by Purdue Pharmaceutical to Canadians.Organization: Health Canada
April 2020
Req # A-2019-000958
All documents related to the natural health product licence submission, assessment, and decision for Ovomet.Organization: Health Canada
April 2020
Req # A-2019-001646
Adverse Reaction Report (AER) for HYDROCHLOROTHIAZIDE, IRBESARTAN. Report number: E2B_02372540.Organization: Health Canada
April 2020
Req # A-2019-001098
All correspondence records between any and/or all three Health Canada officials concerning the publication of the Draft Screening Assessment of Talc September 1, 2018 to December 31, 2018.Organization: Health Canada
April 2020
Req # A-2019-001606
All records between Health Canada and the Canadian Patient Safety Institute (CPSI) and/or Patients for Patient Safety Canada (PFPSC) on the results of the CPSI and PFPSC 2018 public survey related to the labelling of non-prescription health products from January 2018 to December 2019.Organization: Health Canada
April 2020
Req # A-2019-001627
Health Canada reviewer's reports for the Fiasp (insulin aspart injection) New Drug Submission.Organization: Health Canada
April 2020
Req # A-2019-001634
On August 30, 2019 Health Canada was sent an application for approval of a Class 3 Cryotherapy device. Provide all possible details regarding the application and results.Organization: Health Canada
April 2020
Req # A-2019-001749
Copy of Natural Health Products Ingredients Database (NHPID) Issue Form submission and all the related records and reports used to substantiate the safety, efficacy and/or quality of the chemical substance Polylactic acid-glycolic acid copolymer as an encapsulating agent.Organization: Health Canada
April 2020